The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Open accessAbstract
Current drug development in oncology is non-selective as it typically focuses on pathways essential for the survival of all dividing cells. The unique metabolic profile of cancer, which is characterized by increased glycolysis and suppressed mitochondrial glucose oxidation (GO) provides cancer cells with a proliferative advantage, conducive with apoptosis resistance and even increased angiogenesis. Recent evidence suggests that targeting the cancer-specific metabolic and mitochondrial remodeling may offer selectivity in cancer treatment. Pyruvate dehydrogenase kinase (PDK) is a mitochondrial enzyme that is activated in a variety of cancers and results in the selective inhibition of pyruvate dehydrogenase, a complex of enzymes that converts cytosolic pyruvate to mitochondrial acetyl-CoA, the substrate for the Krebs' cycle. Inhibition of PDK with either small interfering RNAs or the orphan drug dichloroacetate (DCA) shifts the metabolism of cancer cells from glycolysis to GO and reverses the suppression of mitochondria-dependent apoptosis. In addition, this therapeutic strategy increases the production of diffusible Krebs' cycle intermediates and mitochondria-derived reactive oxygen species, activating p53 or inhibiting pro-proliferative and pro-angiogenic transcription factors like nuclear factor of activated T cells and hypoxia-inducible factor 1α. These effects result in decreased tumor growth and angiogenesis in a variety of cancers with high selectivity. In a small but mechanistic clinical trial in patients with glioblastoma, a highly aggressive and vascular form of brain cancer, DCA decreased tumor angiogenesis and tumor growth, suggesting that metabolic-targeting therapies can be translated directly to patients. More recently, the M2 isoform of pyruvate kinase (PKM2), which is highly expressed in cancer, is associated with suppressed mitochondrial function. Similar to DCA, activation of PKM2 in many cancers results in increased mitochondrial function and decreased tumor growth. Therefore, reversing the mitochondrial suppression with metabolic-modulating drugs, like PDK inhibitors or PKM2 activators holds promise in the rapidly expanding field of metabolic oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Similarly, herceptin, an antibody that inhibits human epidermal growth factor receptor 2 (HER2) on HER2-positive breast cancers (Eisenhauer, 2001; Slamon et al., 2001) is also selective and effective, but like Gleevec this is an exception in oncology.”
BackgroundInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Cited by
Endometriosis: Etiology, pathobiology, and therapeutic prospects
Saunders, P. T. K., & Horne, A. W. (2021) · Cell · doi:10.1016/j.cell.2021.04.041 · Cited by 961
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
Gerriets, V. A., Kishton, R. J., Nichols, A. G., Macintyre, A. N., Inoue, M., Ilkayeva, O., Winter, P. S., Liu, X., Priyadharshini, B., Slawinska, M. E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76012 · Cited by 731
The pyruvate dehydrogenase complexes: structure-based function and regulation
Patel, M. S., Nemeria, N. S., Furey, W., & Jordan, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.563148 · Cited by 674
The Warburg effect then and now: From cancer to inflammatory diseases
Palsson‐McDermott, E. M., & O'Neill, L. A. J. (2013) · BioEssays · doi:10.1002/bies.201300084 · Cited by 537
The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility
Zhang, S., Hulver, M. W., McMillan, R. P., Cline, M. A., & Gilbert, E. R. (2014) · Nutrition & Metabolism · doi:10.1186/1743-7075-11-10 · Cited by 450
Mitochondria and cancer chemoresistance
Guerra, F., Arbini, A. A., & Moro, L. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.012 · Cited by 323
Michelakis, E. D., Gurtu, V., Webster, L., Barnes, G., Watson, G., Howard, L., Cupitt, J., Paterson, I., Thompson, R. B., Chow, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4583 · Cited by 316
Self-citationThe Metabolic Theory of Pulmonary Arterial Hypertension
Paulin, R., & Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301130 · Cited by 314
Self-citationGlycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia
Peng, F., Wang, J.-H., Fan, W.-J., Meng, Y.-T., Li, M.-M., Li, T.-T., Cui, B., Wang, H.-F., Zhao, Y., An, F., et al. (2018) · Oncogene · doi:10.1038/onc.2017.368 · Cited by 303
The Metabolic Basis of Pulmonary Arterial Hypertension
Sutendra, G., & Michelakis, E. D. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.004 · Cited by 268
Self-citationPhase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Dunbar, E. M., Coats, B. S., Shroads, A. L., Langaee, T., Lew, A., Forder, J. R., Shuster, J. J., Wagner, D. A., & Stacpoole, P. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0047-4 · Cited by 241
Paulin, R., Dromparis, P., Sutendra, G., Gurtu, V., Zervopoulos, S., Bowers, L., Haromy, A., Webster, L., Provencher, S., Bonnet, S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.011 · Cited by 214
“PDH inhibition exists in several models of PAH and cancer and its reactivation (eithermolecularly or by the small molecule dichloroacetate) reverses themitochondrial suppression and established disease (Michelakis et al., 2010; Sutendra and Michelakis, 2013).”
BackgroundSelf-citationIDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123
Shan, C., Zhang, D., Ma, D.-N., Hou, Y.-F., Zhuang, Q.-Q., Gong, Y.-L., Sun, L.-H., Zhao, H.-Y., Tao, B., Yang, Y.-Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01343-y · Cited by 53
Oncogene‐induced cellular senescence elicits an anti‐ Warburg effect
Li, M., Durbin, K. R., Sweet, S. M. M., Tipton, J. D., Zheng, Y., & Kelleher, N. L. (2013) · PROTEOMICS · doi:10.1002/pmic.201200298 · Cited by 43
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
“Cancer cells show aerobic glycolysis, the well-known Warburg effect, and dichloroacetate (DCA) diverts the glucose utilization from aerobic glycolysis to respiration by inhibition of mitochondrial pyruvate dehydrogenase kinase 1 (PDK1) [60, 61].”
BackgroundGaser, O. A., Nasr, M. A., Hussein, A. E., Salah, R. A., Saad, S. M., Ehab, S., Aboomar, N. M., Elmehrath, A. O., Salah, A., Chang, Y.-T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-02807-0 · Cited by 2
Metadata
- Authors
- Sutendra, G., & Michelakis, E. D.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 38-38
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2074171009
- Cited by
- 262
- References
- 96
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.